To mark our outstanding success in REF2021, Gege Li spoke to two of our researchers here at the ICR who have played central roles in improving the use of radiotherapy in the treatment of breast cancer – transforming the lives of many thousands of patients.

To mark our outstanding success in REF2021, Gege Li spoke to several of our researchers here at the ICR who have pioneered improved use of radiotherapy in the treatment of prostate cancer.

To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer.